Pharma BD Deal Intelligence
A $12B stock-and-cash merger that made ICON the world's #2 global CRO, with the combined company hitting $8.25B FY2025 revenue—though a May 2026 Audit Committee probe into improper 2023-2024 revenue recognition forced a restatement and exposed material weaknesses in internal controls.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
ICON acquired rival PRA Health Sciences in a $12 billion deal, positioning the combined company as the second-largest clinical trial services provider with…
ICON concluded its acquisition of contract research organization PRA Health Sciences for approximately $12 billion, creating a combined entity to accelerate…
FY2025 revenue $8,251.3M (+0.8% reported); adjusted EBITDA $1,530.7M (18.6%). Audit Committee investigation found improper revenue adjustments Q3 2023-Q4…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
ICON plc acquired PRA Health Sciences in a deal valued at approximately $12 billion, creating one of the world's largest contract research organizations. PRA shareholders received $80 in cash and 0.4125 ICON shares per PRA share. UPDATE (2026-06): The combined company scaled to the #2 global CRO (FY2025 revenue $8.25B), but in May 2026 ICON disclosed an Audit Committee investigation finding improper revenue recognition in 2023-2024, forcing a restatement of FY2023/FY2024 results and the identification of material weaknesses in internal controls — a governance development that qualifies the prior post-close performance narrative.
$56.7B Global Market
The clinical research organization industry provides outsourced drug development services to pharmaceutical and biotech companies, spanning study design, site management, data management, regulatory submissions, and post-market surveillance. Industry consolidation accelerated in 2020-2021 as scale became critical for decentralized trial capabilities.
The merger created the world's largest or second-largest CRO by revenue (~$6B combined), directly challenging IQVIA for market leadership. The combined entity held strategic partnerships with a majority of top-20 biopharma companies and became #1 or #2 across all key clinical CRO segments.
ICON closed $12B acquisition of PRA Health Sciences, creating world second-largest CRO with 38,000 employees.
First full year combined: $7.74B revenue, 41.2% YoY increase reflecting successful integration.
Revenue grew 4.9% to $8.12B with adjusted EBITDA growth of 15% and EPS growth of 9%.
Revenue $8.28B with 21.0% adjusted EBITDA margin, though growth moderated to 2.0%.
ICON reported FY2025 revenue of $8,251.3M (adj EBITDA $1,530.7M, 18.6%) and disclosed the outcome of an Audit Committee investigation: improper revenue adjustments Q3 2023-Q4 2024 led to restating FY2023 (revenue -$65.3M, net income -$58.1M) and FY2024 (revenue -$92.7M, net income -$52.3M). Prior FY2023/FY2024 statements and quarterly results through Q3 2025 should no longer be relied upon; material weaknesses in internal controls identified as of 12/31/2025.
ICON-PRA created world #2 CRO, grew revenue from ~$5.5B to $8.3B, achieved 21% EBITDA margins.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ICON plc / PRA Health Sciences Inc. (this deal) | 2021 | $12.0B | 54 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |